Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17593332 | 1.00 | KDM4E (0.30) | KDM4EMEN1NPC1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL14745417 | 0.99 | KDM4E (0.30) | KDM4EMEN1NPC1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL14745596 | 0.99 | KDM4E (0.30) | KDM4EMEN1NPC1LMNAMAPT | |
| SCHEMBL14757061 | 0.98 | SLC16A3 (0.32) | SLC16A3 | |
| SCHEMBL17593319 | 0.98 | SLC16A3 (0.32) | SLC16A3 | |
| Trifluoroacetic Acid SCHEMBL14745663 | 0.93 | — | — | |
| SCHEMBL17527120 | 0.90 | NPSR1 (0.32) | MAPTSLC16A3 | |
| SCHEMBL14745691 | 0.87 | IP6K1 (0.37) | KDM4EMEN1NPC1LMNAMAPT | |
| SCHEMBL17536064 | 0.86 | EGLN1 (0.30) | — | |
| SCHEMBL17593161 | 0.86 | NPSR1 (0.31) | SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2750678-B1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS INC (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2016039938-A1 | POLYCYCLIC 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20150038438-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038438-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. | 2015-02-05 | — | — | US | disclosed |
| WO-2013033228-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038438-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | KDM4E 4305/4885MEN1 4630/4885NPC1 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.